Back to Products
CJC-1295+DAC is one of modified synthetic analogues of growth hormone releasing hormone (GHRH). It acts as a growth hormone (GH) secretagogue stimulating levels of GH and insulin-like growth factor 1 (IGF-1), while preserving GH pulsatility. This stimulation in turn is the basis for its effects confirmed in various studies in animals and humans. This peptide contains an additive called DAC - Drug Affinity Complex, which is added to the CJC-1295 molecule via a lysine linker, and provides protection during circulation in the bloodstream. The DAC enhances the pharmacokinetics of the peptide, and allows it to bind to the blood protein albumin, thereby extending the half-life of CJC-1295 relative to other similar analogue molecules and natural GHRH itself.
[1]
In stock
€66.99 Tax included
Quantity:
5 mg
Unit:
1 Vial
Physical Appearance:
White powder
Salt form:
HCl
Peptide Purity:
≥99%
Sequence:
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-Lys(Maleimidopropionyl)-NH2
Molecular Mass:
3775.4
CAS NO.:
863288-34-0
Solubility:
NaCl / Sterile / Bacteriostatic water 1ml/vial
The product is intended for scientific research and development purposes only. Chemical substances shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. Intended only for in-vitro research, such as Receptor-ligand binding studies, Enzyme activity assays, Cell proliferation assays, Cell signaling assays, Epitope mapping, ect.
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
Room temperature (15–25 °C): Up to 3 months Refrigerated (2–8 °C): Up to 6 months Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Before use, allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
Room temperature (15–25 °C): Avoid prolonged storage Refrigerated (2–8 °C): Typically 4–8 weeks Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend using reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, Ipamorelin reconstituted in 0.9% sodium chloride showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to other peptides without supporting stability data.
The shelf life of peptide solutions is limited. Freezing the aliquots will prolong the storage life of the peptide. What is globally accepted for peptides in solution is that they are generally stable for 3 or more weeks at +4°C and for 3-4 months at -20°C. Avoid repeated freeze-thaw cycles, as this can degrade the peptides.
Used solely for in vitro experiments and cannot be:
Used in clinical trials involving humans Administered to humans as part of an experiment or investigation Supplied to another party for human investigational use
Description of CJC-1295+DAC?
The CJC-1295+DAC peptide was made by ConjuChem Biotechnologies up of the first 29 amino acids of GHRH combined with a DAC supplement that allows to prolong the half-life and duration of action of the peptide CJC-1295. GHRH, the growth hormone releasing hormone, has been modified several times to create analogues that would have similar effects to GHRH, since its use is limited by short duration of action. This particular GHRH analogue was created in an attempt to find a more soluble GH secretagogue that could both be easily produced in large quantities and preserve or prolong the effects of GHRH action in the body. Although CJC-1295+DAC is chemically very similar to other GHRH analogues such as Sermorelin or even more to GRF (1-29), which is the most similar to it, they are not identical. Subcutaneous administration of CJC-1295 caused in healthy adults dose-dependent increase in GH and IGF-1 levels, which was well tolerated and safe.
[2]
Overview of Published Research
1. CJC-1295 and Growth Hormone Release
Studies have confirmed that after a single injection of CJC-1295 it increases growth hormone (GH) levels in mice and also in healthy human adults by about 2-10-times, with GH reaching peak levels approximately 2 hours after administration of the peptide and the effects lasting for six or more days thereafter. GHRH analogue increases also the IGF-1 concentration by 1,5-3-fold for 9-11 days, whereas the half-life was 5,8-8,1 d.
Maintaining the physiological effect on GH release is critical in affecting the maximum concentration of the hormone in the blood without adverse reaction or increased side effects. Unlike other GH secretagogues, CJC-1295 preserves normal physiological growth hormone release with unchanged frequency and magnitude of GH secretory pulses when the peptide is administered. However, basal levels of growth hormone can be increased. The CJC-1295+DAC peptide has been shown in research to preserve the physiological effects of GH on protein synthesis, myocardial function, bone density, hyperplasia, blood sugar, lipid metabolism or hypertrophy.
[1] [2]
2. Growth Effect and CJC-1295
Research has indicated that the peptide may be of potential interest in the context of normalizing growth issues. Although children with GH deficiency have a good response to GHRH administration, its therapeutical effects are limited because of very short half-life.
Research has indicated that the peptide may be of potential interest in the context of normalizing growth issues. Although children with GH deficiency have a good response to GHRH administration, its therapeutical effects are limited because of very short half-life.
[3]
3. CJC-1295 and Infertility
Scientists have found some in vivo and in vitro evidence that ovarian follicular cycle and ovulation is influenced and stimulated by IGF-1 hormones, and probably also by the release of growth hormone. It is for this reason that the CJC-1295 peptide, as well as other GHRH analogues, could be of research interest in the context of inducing ovulation in infertile women. This is suggested by research done back in the early 1990s and confirmed by another that investigated superovulation in animals. Growth hormone and IGF-1 levels rose significantly just during ovulation and exogenous administration of growth hormone secretagogues, such as CJC-1295, induced ovulation. It has also been suggested that the peptide and other GHRH analogues could potentially act on sperm production in men and may be relevant to research into male infertility. Further research will, hopefully, clearly define the precise role of GH in the induction of ovulation, and the minimum dose of GH needed to sensitize the ovary, as well as influences on men infertility.
[4]
References
M. Ionescu and L. A. Frohman, "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog," J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. Sam L. Teichman et al., „Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults, 91(3):799-805, Epub 2005 Dec 13. M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse," Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, "Clinical use of growth hormone-releasing factor for induction of superovulation," Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991.
Related products
Hexarelin 5mg
Hexarelin, also known as Examorelin, is a synthetic GH releasing hexapeptide, which activates growth hormone secretagogue receptor (GHSR) in the brain area. It is also ghrelin analog, similarly to other peptides such as GHRP-6. Beyond GH release and neuroendocrine effects, hexarelin might have also direct cardiovascular actions and cardioprotective...
In stock
€29.99 Tax included
Ipamorelin 5mg
Ipamorelin represents a synthetic pentapeptide derived from GHRP-1, which has a very potent growth hormone (GH) releasing properties with efficacy and potency comparable to GHRP-6, both in vitro and in vivo. Unlike other GH secretagogues, ipamorelin very surprisingly does not induce a significant increase in adrenocorticotropic hormone (ACTH) or cortisol...
In stock
€29.99 Tax included
GHRP-6 5mg
Peptide GHRP-6, also known as growth hormone-releasing peptide 6, is a synthetic hexapeptide that specifically stimulates natural growth hormone release from the anterior pituitary gland by pituitary somatotrophs. It acts by binding to ghrelin receptors and mimics the effects of ghrelin – natural endogenous hormone. It has been researched for several...
In stock
€25.99 Tax included
CJC-1295+DAC is one of modified synthetic analogues of growth hormone releasing hormone (GHRH). It acts as a growth hormone (GH) secretagogue stimulating levels of GH and insulin-like growth factor 1 (IGF-1), while preserving GH pulsatility. This stimulation in turn is the basis for its effects confirmed in various studies in animals and humans. This peptide contains an additive called DAC - Drug Affinity Complex, which is added to the CJC-1295 molecule via a lysine linker, and provides protection during circulation in the bloodstream. The DAC enhances the pharmacokinetics of the peptide, and allows it to bind to the blood protein albumin, thereby extending the half-life of CJC-1295 relative to other similar analogue molecules and natural GHRH itself.
[1]
Our Reviews
4.9/5 out of 502 reviews
Always good
Grate !!!
Card Payment was not possible
Toto bol druhy pokus
CJC-1295 + DAC 5mg
* * * * * 4.0
€66.99 Tax included
×
This product is delivered in lyophilized powdered or gel form, which ensures the preservation of the highest quality of the preparations. Bacteriostatic water is required to prepare the solution.
×
Why does the peptide vial look empty?
Our peptides are supplied completely without Mannitol filler. Mannitol is a filler that is added to peptides as a bulking agent. It offers no therapeutic benefit. Peptides are microscopic and minuscule without fillers like mannitol. Lyophilized peptide with mannitol filler will look like what we call a hockey puck. Without that filler it looks like you have a small amount or nothing in your vial even though you do. Individual peptides vary significantly in appearance within vials, even between 2 vials containing the same amount. In vials, they can look like a powder, a few smaller hockey pucks, or even just a few spots. Some peptides may look like a gel or an oil film; they are very difficult to see. Apart from the appearance, the quality and peptide content remains unchanged, which continues to be regularly confirmed by third-party analyses.